View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, Jan. 8, 2014 (HealthDay News) -- Farxiga (dapaglifozin) has been approved by the U.S. Food and Drug Administration to treat adults with type 2 diabetes, the agency said Wednesday in a news release.
The drug, to be used for blood sugar control along with proper diet and exercise, is designed to prevent re-absorption of glucose by the kidneys. Farxiga's safety and effectiveness were established in clinical trials involving more than 9,400 people with type 2 diabetes. The most common side effects were fungal infections and urinary tract infections. More serious adverse reactions included dehydration, hypotension, and fainting.
An abnormally high number of clinical trial participants who used Farxiga developed bladder cancer, so the drug isn't recommended for people with active bladder cancer. People with a history of the disease should consult a physician before using the drug, the FDA said.
The agency said it is requiring six post-marketing studies to further evaluate issues such as risk for cardiovascular disease, bladder cancer risk, use among children and pregnant women, and effects on the liver.
The drug is marketed by Princeton, N.J.-based Bristol-Myers Squibb and Wilmington, Del.-based AstraZeneca.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top